Skip to main content
Log in

Hepatitis C — pipeline update

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: Antiviral activities of selected direct antiviral agents.

References

  1. Ghany, M. G., Strader, D. B., Thomas, D. L. & Seeff, L. B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49, 1335–1374 (2009).

    Article  CAS  Google Scholar 

  2. The 61st Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2010. Hepatology 52 (Suppl. S1), iiA–ivA, 1A–1352A (2010).

  3. Sarrazin, C. & Zeuzem, S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138, 447–462 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author declares no competing financial interests.

Related links

Related links

FURTHER INFORMATION

ClinicalTrials.gov

HCV New Drug Research

Thomson Pharma Partnering

Rights and permissions

Reprints and permissions

About this article

Cite this article

Melnikova, I. Hepatitis C — pipeline update. Nat Rev Drug Discov 10, 93–94 (2011). https://doi.org/10.1038/nrd3361

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3361

  • Springer Nature Limited

This article is cited by

Navigation